<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390477</url>
  </required_header>
  <id_info>
    <org_study_id>COVID.PROB</org_study_id>
    <nct_id>NCT04390477</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of a Probiotic in COVID-19</brief_title>
  <official_title>The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioithas SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioithas SL</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture
      in the improvement of symptoms, the reduction in the number of days of hospitalization and
      the increase in the percentage of patients with negative PCR after infection with the
      coronavirus SARS-CoV-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators hypothesize a positive effect of probiotic on the gut
      microbiome that could led to produce a less severe clinical evolution of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Random numbers table. One branch placebo and other one no intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cases with discharge to ICU.</measure>
    <time_frame>30-days</time_frame>
    <description>Percentage of patients with discharge to ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with home discharge.</measure>
    <time_frame>30-days</time_frame>
    <description>Percentage of patients with home discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality.</measure>
    <time_frame>30-days</time_frame>
    <description>Percentage of deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety assessed by number of adverse events.</measure>
    <time_frame>30-days</time_frame>
    <description>Number of adverse events that occur during the treatment period, attributable or not to the intervention product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients.</measure>
    <time_frame>30-days</time_frame>
    <description>Number of new cases of positive SARS-Cov-2 infection by PCR analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with negative PCR result for SARS-CoV-2 infection.</measure>
    <time_frame>30-days</time_frame>
    <description>Percentage of patients with negative PCR for SARS-CoV-2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill od containing 1x10E9 cfu of the probiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of SARS-Cov.2 infection using the PCR and that
             require admission to the hospitalization area.

        Exclusion Criteria:

          -  Inability or refusal to sign informed consent.

          -  Allergy or intolerance to the intervention product or its components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Navarro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital universitario del Vinalopo, Elche, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Navarro</last_name>
    <phone>0034623022586</phone>
    <email>laura.navarro@bioithas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario del Vinalopó</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03293</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Navarro</last_name>
      <phone>968278800</phone>
      <email>vnavarro@vinaloposalud.com</email>
    </contact>
    <investigator>
      <last_name>Maria Isabel Perez-Soto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Navarro</last_name>
      <phone>965721200</phone>
      <email>vnavarro@vinaloposalud.com</email>
    </contact>
    <investigator>
      <last_name>Maykel Ayo-González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

